Siga Technologies Inc.
SIGA Healthcare Drug Manufacturers Specialty & Generic
Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue fell 49.5%, EPS fell 66.0% and free cash flow fell 76.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
Follow SIGA
Siga Technologies Inc. (SIGA) P/E ratio
Siga Technologies Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 102× (August 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 18.3× | 149.37% |
| FY2024 | 7.3× | 20.20% |
| FY2023 | 6.1× | (59.66%) |
| FY2022 | 15.1× | 87.37% |
| FY2021 | 8.1× | (20.11%) |
| FY2020 | 10.1× | — |
| FY2019 | 0.0× | — |
| FY2018 | 1.5× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 18.4× | 0.94% |
| Dec 2025 | 18.3× | 106.60% |
| Sep 2025 | 8.8× | 55.26% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LFCR Lifecore Biomedical, Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| SIGA Siga Technologies Inc. | n/m |
| ACB Aurora Cannabis Inc. compare | n/m |
| BIOA BioAge Labs, Inc. compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| ANIK Anika Therapeutics Inc. compare | n/m |
| ORGO Organogenesis compare | n/m |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)